Data from Rexahn Pharmaceuticals' Phase I Trial of RX-0201 (Archexin) to Be Presented at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago
ROCKVILLE, Md.--(BUSINESS WIRE)--
Rexahn Pharmaceuticals, Inc. (OTC BB:RXHN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs, today announced that Dr. John Marshall, Principal Investigator of Phase I clinical trial of the Company's lead cancer compound RX-0201 (Archexin), will present results of the clinical study at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 1-5, 2007 at McCormick Place in Chicago, Illinois.
The presentation, entitled, "A Phase I Trial of RX-0201 (AKT anti-sense) in Patients with Advanced Cancer," is scheduled for Sunday, June 3, 2007 at 9am Central Time.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a biopharmaceutical company leveraging its unique technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy. For Additional information about Rexahn visit www.rexahn.com.
Source: Rexahn Pharmaceuticals, Inc.
Released May 30, 2007